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Abstract
Purpose The adequacy of pain management for individuals
with cancer who receive outpatient chemotherapy is unclear.
The primary objective of this study was to assess pain preva-
lence and intensity in such patients. The secondary objectives
included assessment of pain management with the pain man-
agement index (PMI) and exploration of predictors of inade-
quate pain management.
Methods Cancer patients who received outpatient chemother-
apy were enrolled. Patients were required to complete ques-
tionnaires covering demographic data and including the Brief
Pain Inventory and the Distress Thermometer and Impact
Thermometer. The PMI score was determined twice with an
interval of at least 3 weeks.
Results Of the 740 patients enrolled in the study, 524 individ-
uals (70.8%) completed all questionnaires. Totals of 282 pa-
tients (53.8%) and 264 patients (50.4%) reported pain at base-
line and follow-up, respectively, with ∼14% of patients having
moderate or severe pain at each assessment. Totals of 365
patients (69.7%) at baseline and 320 patients (61.1%) at
follow-up reported pain or were prescribed analgesics, with
the rate of inadequate pain management for these patients
being 39.7 and 51.6%, respectively. Multivariable analysis
for 418 patients (79.8%) who had pain or required analgesics
at baseline or follow-up (or both) revealed that the most sig-
nificant predictor of inadequate pain management was depres-
sive state.
Conclusions Pain in cancer patients receiving outpatient che-
motherapy is prevalent and at risk for undertreatment. Pain
management should be assessed on a regular basis and is
likely to be improved by screening for depression.
Keywords Cancer . Pain . Outpatient chemotherapy . Pain
management index (PMI) . Inadequate painmanagement .
Depressive state
Introduction
Pain is one of the most frequent and burdensome symptoms in
individuals with cancer [1–3]. A systematic review of 52 stud-
ies found that pain prevalencewas 33% in cancer patients after
curative treatment, 59% in those undergoing anticancer ther-
apy, and 64% in those with advanced or metastatic disease [4].
The prevalence of moderate or severe pain in patients under-
going anticancer treatment and in those with advanced, meta-
static, or terminal disease was 36 and 45%, respectively [4].
As a result of the recent shift in cancer care from the hos-
pital to the outpatient setting, the number of cancer patients
who receive outpatient chemotherapy has increased [5, 6].
Given that unrelieved pain can interfere with physical function
and quality of life, inadequate pain management can delay or
disrupt chemotherapy [7]. The adequacy of pain management
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in cancer patients undergoing outpatient chemotherapy is un-
clear, however.
Many studies have applied the pain management index
(PMI) to determine the adequacy of analgesic pain manage-
ment in cancer patients and to explore various predictors of
inadequate pain management [2, 8, 9]. A meta-analysis of 20
studies published between 2007 and 2013 found that the prev-
alence of inadequate pain management as determined by the
PMI ranged from 4 to 68%, with a weighted mean value of
31.8% [2]. Patient characteristics such as age, sex, and educa-
tion have been implicated as predictors of inadequate pain
management [8, 9]. However, as far as we are aware, no pre-
vious study has found an association between the PMI and
mental state such as depression, which is a common symptom
in cancer patients [10]. A systematic review of 14 studies
revealed that the mean prevalence of the coexistence of de-
pression and pain in cancer patients was 36.5% [11].
Moreover, an interaction between depression and pain is well
documented in such patients [7, 12]. Depression may there-
fore be related to inadequate pain management.
Two cross-sectional studies and one retrospective study
have previously applied the PMI to cancer patients in Japan
[13–15]. To our knowledge, however, no longitudinal study
with this index has been conducted in Japan. We have there-
fore now performed an observational longitudinal study of
pain with the PMI in cancer patients undergoing outpatient
chemotherapy at Kyushu University Hospital. The primary
objective of our study was to assess pain prevalence and in-
tensity in these patients. The secondary objectives were to
assess the adequacy of pain management with the PMI and
to explore predictors, including depressive state, of inadequate
pain management during the course of outpatient
chemotherapy.
Patients and methods
Study design and patients
From May 2011 to December 2013, we enrolled cancer out-
patients who were newly to receive chemotherapy in the
Outpatient Chemotherapy Unit (OCU) at Kyushu University
Hospital in Japan. Patients were eligible for inclusion in this
observational longitudinal study if they were 20 years of age
or older, had been diagnosed with a solid tumor or hemato-
logic malignancy, and had newly started outpatient chemo-
therapy in the OCU during the study period. Patients who
had been previously treated with a chemotherapy regimen in
the OCU before the onset of the present study in May 2011
and who newly visited the OCU for treatment with another
regimen were also eligible. Patients were excluded if they
were unable to complete questionnaires because of a visual
disorder, severe mental or cognitive disorder, or inability to
understand the Japanese language. Patients who were to re-
ceive preoperative chemotherapy were also excluded because
their treatment schedule was not consistent with our data col-
lection schedule.
Data collection
After they had provided informed consent, patients were re-
quired to fill in a questionnaire requesting basic information
including age, sex, marital status, employment, and education.
Data for the assessment of pain management were collected at
baseline (when patients first received chemotherapy in the
OCU) and at follow-up (at least 3 weeks later according to
treatment schedule) with the use of questionnaires including
the Brief Pain Inventory (BPI) and the Distress Thermometer
and Impact Thermometer (DT & IT). Given that new chemo-
therapy regimens are usually initiated in the inpatient setting
in Japan, most patients were required to complete the pain
assessments on day 1 of the second cycle and on day 1 of
the third cycle of chemotherapy. However, patients who were
treated with weekly or biweekly cycles of chemotherapy were
required to complete the follow-up assessment at 3 or 4 weeks
after the baseline assessment, respectively. Patients were ex-
cluded from the follow-up assessment if they did not visit the
OCU for chemotherapy within 4 weeks after the day sched-
uled for the assessment. Clinical information was collected
from medical records.
Measures
Pain was measured with the use of the validated Japanese
version of the BPI, which asks cancer patients to describe their
pain intensity at its worst, least, and average during the previ-
ous 24 h as well as their current pain intensity according to a
Numeric Rating Scale from 0 (not present) to 10 (as bad as
you can imagine) [15].
The PMI is a frequently used and well-validated tool for
assessment of the adequacy of pain management for patients
who have pain or taken analgesics [1, 8, 13]. It is calculated by
subtraction of the patient-rated pain score from the analgesic
drug score [8]. The patient-rated pain score is categorized as 0
(no pain), 1 (1–4, mild pain), 2 (5 or 6, moderate pain), or 3
(7–10, severe pain) on the basis of the worst pain score on the
BPI. The analgesic drug score is determined by the most po-
tent analgesic drug administered: 0 (no analgesic drug), 1
(nonopioid), 2 (weak opioid), or 3 (strong opioid). The PMI
can thus range from −3 (a patient with severe pain receiving
no analgesic drug) to +3 (a patient receiving a strong opioid
and reporting no pain). Negative PMI scores are indicative of
inadequate pain management, and scores of 0 or higher are
considered to reflect adequate pain management.
To explore the predictors of inadequacy of pain manage-
ment, we measured depressive state using the DT& IT, a brief
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screening tool for detection of depression in cancer patients
[16]. The DT& ITasks patients to identify the level of distress
and the impact of the distress on daily life activity in the
previous week using two visual analog scales with a scoring
range from 0 (not present) to 10 (as bad as you can imagine)
[16]. Patients who score 4 or higher on the distress scale and 3
or higher on the impact scale are considered to have a depres-
sive state, with these cutoffs having been validated [16].
Statistical analysis
Differences in characteristics between patients included in
or excluded from the analysis were evaluated with
Student’s t test or the chi-square test. To examine predic-
tors of inadequate pain management, we performed
univariable and multivariable logistic regression analyses.
Patients without pain and not taking analgesics at both
assessments were excluded from logistic regression analy-
sis because they were not considered to be at risk for pain.
The outcome variable was the PMI score, which was di-
chotomized as 0 for a PMI of <0 at baseline or follow-up
(or both) for inadequate pain management and as 1 for a
PMI of ≥0 at both assessments for adequate pain manage-
ment. Independent variables included age, sex, marital sta-
tus, employment, education, current chemotherapy, and
depressive state. For multivariable logistic regression anal-
ysis, independent variables were selected with a stepwise
procedure that was repeated until all predictors in the mod-
el met the criterion of a P value of ≤0.10. Statistical sig-
nificance was set at a P value of <0.05. All statistical anal-




A total of 740 cancer patients were enrolled in the study,
524 (70.8%) of whom completed all questionnaires and
were included in the statistical analysis (Fig. 1). A total
of 216 patients (29.2%) was thus excluded from the anal-
ysis. The main reason for failure to complete question-
naires was cessation of current cancer treatment because
of disease progression or a change of treatment plan such
as transition to other chemotherapy or palliative care.
Significant differences in site of primary malignancy, stage
of disease, and current chemotherapy were apparent be-
tween patients included in the analysis and those excluded
(Table 1).
Fig. 1 Flow diagram of patient
enrollment. a Number of patients
who completed questionnaires
including basic information. b
Number of patients who
completed assessment at baseline
or follow-up. c Patient factors
included distress, prolongation or
cessation of chemotherapy,
change in treatment plan, or death
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Common primary sites for the malignancies of the 524
patients analyzed included colon-rectum (18.3%), pancreas
(17.7%), breast (15.1%), and lung (11.3%), with 16.0% of
individuals having a hematologic malignancy (Table 1).
There was no significant difference in the distribution of pri-
mary cancer sites between these patients and the entire patient
population treated in the OCU during the study period (data
not shown). Most individuals had an Eastern Cooperative
Oncology Group performance status (PS) of 0 (44.6%) or 1
(51.3%), and 175 patients (33.4%) received adjuvant
chemotherapy.
Pain prevalence and analgesic prescription
Totals of 282 patients (53.8%) and 264 patients (50.4%) re-
ported pain at baseline and follow-up, respectively. Seventy-
three patients (13.9%) at baseline and 74 patients (14.1%) at
follow-up reported moderate or severe pain (Fig. 2a). A total
of 259 patients (49.4%) at baseline and 181 patients (34.5%)
at follow-up had analgesics prescribed, with 48 patients
(9.2%) at baseline and 51 patients (9.8%) at follow-up receiv-
ing weak or strong opioids (Fig. 2b). At baseline, 106 patients
(20.2%) with pain received no analgesic, with 22 (4.2%) of
Table 1. Patient characteristics (N = 740)
Characteristic Patients in the analysis at
baseline and follow-up
(N = 524, 70.8%)
Patients not in the analysis at
baseline and follow-up
(N = 216, 29.2%)
Pa
N (%) N (%)
Age (years)
Mean ± SD [60.8 ± 12.1] [62.6 ± 10.9] 0.069
Median (range) [63 (21–86)] [63 (26–84)]
Up to 63 279 (53.2) 110 (50.9)
64 or higher 245 (46.8) 106 (49.1) 0.566
Sex
Male 261 (49.8) 119 (55.1)
Female 263 (50.2) 97 (44.9) 0.191
Marital status
Married/partnered 401 (76.5) 164 (75.9)
Other 123 (23.5) 52 (24.1) 0.343
Employment
Employed (full or part time) 172 (32.8) 64 (29.6)
Homemaker 144 (27.5) 43 (19.9)
Not in work 208 (39.7) 99 (45.8)
Unknown 0 (0) 10 (4.6) 0.063
Education
Junior high school 67 (12.8) 25 (11.6)
High school 268 (51.1) 89 (41.2)
College or university 189 (36.1) 89 (41.2)
Unknown 0 (0) 13 (6.0) 0.263
Primary cancer site
Lung or chest 62 (11.8) 42 (19.4)
Breast 79 (15.1) 16 (7.4)
Colon-rectum 96 (18.3) 27 (12.5)
Stomach or duodenum 22 (4.2) 20 (9.3)
Esophagus 14 (2.7) 9 (4.2)
Pancreas, bile duct, or liver 130 (24.8) 29 (13.4)
Uterus or ovary 13 (2.5) 10 (4.6)
Hematologic malignancy 84 (16.0) 48 (22.2)
Other 24 (4.6) 15 (6.9) <0.001
UICC disease stage
I 28 (5.3) 3 (1.4)
II 74 (14.1) 16 (7.4)
III 68 (13.0) 19 (8.8)
IV 166 (31.7) 87 (40.3)
Recurrence 101 (19.3) 41 (19.0)
Unclassifiable 84 (16.0) 48 (22.2)
No staging or unknown 3 (0.6) 2 (0.9) 0.002
Current chemotherapy
First line 225 (42.9) 117 (54.1)
Second line or higher 124 (23.7) 68 (31.5)
Adjuvant 175 (33.4) 31 (14.4) <0.001
UICC Unio Internationalis Contra Cancrum
aP values were determined with the chi-square test with the exception of that for mean age (Student’s t test)
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these patients having moderate or severe pain and three still
not being treated with any analgesic drug at follow-up. At
follow-up, 139 patients (26.5%) with pain were not treated
with an analgesic drug, with 33 (6.3%) of these patients
reporting moderate or severe pain.
Adequacy of pain management
Totals of 365 patients (69.7%) at baseline and 320 patients
(61.1%) at follow-up were in pain or taking analgesics (or
both), with 145 of the 365 patients (39.7%) at baseline and
165 of the 320 patients (51.6%) at follow-up receiving
inadequate pain management (Fig. 3). In addition, pain of 71
of the 145 patients (49.0%) receiving inadequate pain man-
agement at baseline was still undertreated at follow-up.
Predictors of inadequate pain management
We excluded patients who were without pain and not taking
analgesics at both assessments from the analysis of predictors
of inadequate pain management. A total of 418 of the 524
patients (79.8%) was thus included in this analysis. The results
of univariable and multivariable analysis performed to identi-
fy potential predictors of inadequate pain management are
Fig. 2 Pain score (a) and
analgesic score (b) for 524
patients eligible for analysis at
both baseline and follow-up
Fig. 3 Pain management index
for 365 patients at baseline and
320 patients at follow-up who
were in pain or taking analgesics
(or both)
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summarized in Table 2. Multivariable analysis revealed that
age, marital status, adjuvant chemotherapy, and depressive
state were significantly associated with inadequate pain man-
agement. The presence of a depressive state was the strongest
predictor of inadequate pain management, with an odds ratio
(OR) of 2.05 (95% confidence interval [CI] of 1.21–3.55,
P = 0.006) in univariable analysis and an OR of 2.20 (95%
CI of 1.30–3.84, P = 0.003) in multivariable analysis.
Discussion
Our study has found that 53.8% of cancer patients experienced
pain at baseline, with 13.9% reporting moderate or severe
pain, and that 50.4% of patients experienced pain at follow-
up, with 14.1% reporting moderate or severe pain. The pro-
portion of patients with moderate or severe pain was similar to
the value of 15% reported for a previous study conducted in
Japan [6].
A previous analysis compared the adequacy of pain man-
agement in cancer patients between two sets of studies pub-
lished between 1994 and 2007 or after 2008 and found that the
mean prevalence of inadequate pain management declined
from 43.4 to 31.8% [2]. Previous cross-sectional studies with
small numbers of cancer patients in Japan published between
1992 and 2004 found that the rate of inadequate pain manage-
ment ranged widely from 27 to 70% [13, 15]. As far as we are
aware, no prospective study of the adequacy of pain manage-
ment based on the PMI in cancer patients in Japan has been
published since 2005. In our study, 39.7 and 51.6% of pa-
tients with pain or taking analgesics received inadequate
pain management at baseline and follow-up, respectively.
The rate of inadequate pain management in our study is
thus higher than that recently determined worldwide [2].
In addition, although it included patients not currently re-
ceiving cancer treatment, a previous longitudinal study of
cancer outpatients found rates of inadequate pain manage-
ment at baseline and after 1 month of follow-up lower than
those determined in the present study [1]. Our findings
therefore imply that pain management for cancer patients
may not have improved in Japan in contrast to that in other
countries. The facts that most patients had a good PS and
that those receiving adjuvant chemotherapy were included
in our study may have contributed to the relatively high
Table 2. Predictors of inadequate pain management




P OR (95% CI) P OR (95% CI)
Age (years)
Up to 63 53.3% (122/229) 1.00 1.00
64 or higher 61.4% (116/189) 0.10 1.39 (0.94–2.07) 0.048 1.49 (1.00–2.24)
Sex
Male 54.8% (109/199) 1.00
Female 58.9% (129/219) 0.39 1.18 (0.80–1.75)
Marital status
Married/partnered 54.4% (173/318) 1.00 1.00
Other 65.0% (65/100) 0.06 1.55 (0.98–2.50) 0.038 1.64 (1.03–2.66)
Job
Other 58.3% (147/252) 1.00
Not in work 54.8% (91/166) 0.48 0.87 (0.58–1.29)
Education
College or university 59.1% (88/149) 1.00
Junior high school / High school 55.8% (150/269) 0.51 0.87 (0.58–1.31)
Current chemotherapy
First line or more 54.0% (147/272) 1.00 1.00
Adjuvant 62.3% (91/146) 0.10 1.41 (0.93–2.13) 0.048 1.53 (1.00–2.34)
Depressive state
No 53.8% (183/340) 1.00 1.00
Yes 70.5% (55/78) 0.006 2.05 (1.21–3.55) 0.003 2.20 (1.30–3.84)
OR odds ratio, CI confidence interval
a 418 patients who had pain or required analgesics at baseline or follow-up (or both)
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rates of inadequate pain management. Previous studies
have found that a better PS and early disease stage are
positive predictors of inadequate pain management, sug-
gesting that patients in better condition tend to be consid-
ered to be in less pain [1, 9, 13]. Moreover, a previous
study found that pain in patients with nonadvanced cancer
current ly receiving cancer therapy tended to be
undertreated compared with that in patients with advanced
cancer currently undergoing such therapy [1]. Indeed, we
found that adjuvant chemotherapy was a significant predic-
tor of inadequate pain management with an OR of 1.53
(95% CI of 1.00–2.34, P = 0.048) in multivariable
analysis.
To our knowledge, our study is the first to show an
association between depressive state and inadequate pain
management estimated with the PMI. Undertreatment of
pain is generally attributed to an inadequate use of opi-
oids due to barriers related to physicians, patients, fam-
ily members, institutions, and society [9]. Patient-related
barriers have been shown to include cognitive or affec-
tive factors such as depression and adherence to analge-
sic treatment [12, 17], consistent with our finding that a
negative PMI score was associated with depressive
state. Given that depression is difficult to diagnose in
cancer patients because of an overlap with cancer symp-
toms and adverse effects of treatment, underrecognition
of depression is a concern [10]. Early intervention with
palliative care for physical and psychosocial symptoms
in patients with metastatic non–small cell lung cancer
has been found to contribute to prolongation of survival
[18]. Our findings therefore highlight the importance of
both physical and mental assessment in cancer patients
receiving chemotherapy. If uncontrolled pain and de-
pressive state are detected, physicians should consider
consultation with a palliative care specialist in order to
prevent prolongation or cessation of chemotherapy.
There are several limitations to our study. First, the en-
rolled patients included those with various cancer diagno-
ses, disease stages, and chemotherapy regimens. Our re-
sults therefore are not necessarily generalizable to specific
patient populations. Second, given that the study was per-
formed at a single institution and in a university hospital,
the results may not be generalizable to outpatients receiv-
ing chemotherapy in regional hospitals. Third, we did not
perform physical examinations or medical imaging to clar-
ify the cause and mechanism of pain. Given that manage-
ment of neuropathic pain is more challenging than that of
nociceptive pain, the existence of neuropathic pain may
have affected our results for inadequate pain management.
Finally, as pointed out in previous studies [1, 9], the PMI
does not take into account actual administration (as op-
posed to prescription) of analgesic drugs. Moreover, the
PMI does not reflect patient satisfaction with pain
management because it is calculated from pain intensity
and the most potent analgesic drug prescribed [2].
In conclusion, pain is prevalent in cancer patients receiving
outpatient chemotherapy and is thus a problem that warrants
attention. Physicians should also be aware that depression
occurs often in cancer patients and can be an obstacle to pain
control. Given that symptoms may change during chemother-
apy, assessment of pain management should be performed on
a regular basis, and screening for depressive state should be
conducted to improve such management.
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